Laboratorios Rovi : CMD 2021: confidence on the approval of Risperidone-ISM to drive the next phase of growth
>Strong confidence on the approval of ISM-Risperidone - Rovi held its CMD 2021 presentation, signalling a stronger focus on the ISM-Risperidone project. Management was optimistic on the regulatory approval of ISM-Risperidone, expecting the EU launch to start in Q2 2022 in Germany and to be followed by UK (Q3 2022), Spain (Q4 2022), Italy (Q1 2023) and other EU countries in 2023 whilst it expects marketing authorisation in the US to be granted in Q3 2022. In Europe aft...Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.